皮质类固醇治疗在耐火性胸腺瘤患者中显著的抗瘤疗效
Tomohiro Tanaka1, Yasushi Goto2, Ken Masuda2
1Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Respiratory Medicine and Infectious Diseases, Niigata University Medical & Dental Hospital, 1-757 Asahimachi-dori, Chuo Ward, Niigata City, 951-8510, Japan.
Respiratory investigation
|July 4, 2024
概括
皮质类固醇在治疗胸腺瘤方面具有临床价值,超过一半的患者出现部分反应. 这项研究强调了它们的有效性,特别是在世卫组织B型瘤中,没有观察到严重的不良事件.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
背景情况:
- 有限的综合性研究存在于皮质类固醇对侵袭性胸腺瘤的疗效.
- 病例报告表明,皮质类固醇可以缩小化疗后或手术失败后的胸腺瘤病变.
研究的目的:
- 评估皮质类固醇单独治疗的抗瘤效应和生存结果在侵袭性胸腺瘤患者中.
主要方法:
- 对13名局部晚期或转移性胸腺瘤患者进行了回顾性审查,这些患者接受了皮质类固醇治疗.
- 使用Cox的比例危险模型和Kaplan-Meier方法对生存因子进行分析.
主要成果:
- 53.8%的部分反应,38.5%观察到稳定的疾病.
- 中位数无进展生存时间为5.7个月;中位数整体生存时间为25.3个月.
- 世卫组织B亚型胸腺瘤对皮质类固醇的反应率更高 (75%);没有发生3级以上的不良事件.
结论:
- 皮质类固醇证明了临床价值,作为对胸腺瘤的治疗选择.
- 皮质类固醇单疗是侵袭性胸腺瘤的可行选择,特别是世卫组织B亚型的B亚型.
- 对最佳剂量和患者选择的进一步研究是有必要的.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
114
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
114
01:27Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K